2027
2026
البوستر
Photos
البوستر
A huge congratulations and thank you to the organizing and scientific committees of the 15th Annual #SSBMT #EBMT 2026 Highlights! ???????? Thank you for building such an exceptional program. Bringing the best of @EBMT highlights to our region resulted in
Huge thanks to all the dedicated nurses who stayed until the very end of the Annual Saudi Hem/Onc Nurses meeting! We appreciate the rich agenda and the incredible participation of the @EBMTNurses Group. Looking forward to next year
Videos
You can watch us live. 15th Annual Conference of SSBMT/EBMT 2026 Highlights.
Photos
البوستر
Videos
1 Integration of Menin Inhibitors in the therapy of AML | Muteb Althomali | | 30 JAN 2026
Philadelphia positive ALL -Best First Line Therapy | Nahla Shihata | 30 JAN 2026
CAR-T vs Bispecific Antibodies in Aggressive Lymphoma | Sameer Alamoudi | 30 JAN 2026
Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Mubarak Almansour| 30JAN 2026
Is there still a role for ASCT in Mantle Cell Lymphoma | Reyad Dada | 30 JAN 2026
HIV Associated Lymphomas | Hafiz Malhan | 30 JAN 2026
Frontline Management in Multiple Myeloma | Ayman Alhejazi | 30 JAN 2026
ALL:How does the future look like w/ Incorporation of upfront Novel therapies | Saleem Eldadah
CAR-T vs Bispecific Antibodies in Myeloma—Bridging Strategies& supportive measures|Abdullah Alsaleh
MRD Negativity in Multiple Myeloma: A New Treatment Endpoint| Ghazi Alotaibi | 30 JAN 2026
Plasma Cell Leukemia – Update on therapy SOC | Majed Alahmadi | 30 JAN 2026
Emerging role of BCMA targeting in management of RRMM | Ghazi Alotaibi | 30 JAN 2026
Gene Therapies: A New Era in Hemoglobinopathies | Ihab Elehmaidi | 30 JAN 2026
Gene Therapy for SCD and TDT — Clinical and Economic Reality | Mohsen Alzahrani | 30 JAN 2026
Managing Challenging Cases: Sickle Cell disease | Gad Allah Ali | 30 JAN 2026
Emerging Therapies in β-Thalassemia — Luspatercept and Beyond | Abdullah Alzayed | 30 JAN 2026
Challenges in Thalassemia for Precision Medicine: Evidence Based Research| Soad Aljaouni|30 JAN 2026
CML 2025:Achieving Treatment-Free Remission—Patient Selection Algorithm | Ihab Elhemaidi |30JAN 2026
MPNs: JAK Inhibitors vs New Pathway Inhibitors— When to Switch Therapy | Sultan Altouri |30 JAN 2026
GVHD 2025: New Predictive Biomarkers and Treatment Algorithms | Naif Aljohani | 30 JAN 2026
Eosinophilic Updates to Old Approaches | Osman Radhwi | 30 JAN 2026
Neutrophilia other than CML | Hanan Hamed | 31 JAN 2026
Fixed duration Novel agents’ combinations in CLL upfront therapy | Ahmed Absi | 31 JAN 2026
Hodgkin Lymphoma–therapy sequencing in the era of upfront biologic therapy |Ahmed Barefah |31JAN2026
Richter’s Transformation | Mohammed Almakadi | 31 JAN 2026
Complicated cases of thrombosis – challenges in management | Ashraf Warsi | 31 JAN 2026
Cancer Associated Thrombosis (CAT) | Sarah Sewaralthahab | 31 JAN 2026
Overview on Platelets Products in Clinical Practice | Salwa Hindawi | 31 JAN 2026
Lymphoma mimickers & Diagnostic Traps | Alfadel Alshaibani | 31 JAN 2026
2025
2024
البوستر
2023